Bcl-2 combined BTK inhibitors for the treatment of chronic lymphocyte lymphoma
-
Last Update: 2020-07-13
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Ascentage Pharma, which is developing new treatments for cancer, chronic hepatitis B and aging disorders, today announced a clinical trial with AstraZeneca to study aPG-2575 (a selective Bcl-2 inhibitor) of AstraZeneca's acarutlabinib (Brutontyinine kinase inhibitor) to treat recurable and difficult-treatedlymphoma (CLL)CLL/SLL is a hemovirus caused by mature B-cell tumors and is the most common form of adult leukemia in North America and Europe, accounting for approximately 30% of all leukemia casesAlthough patients have a clear initial response to current first-line treatment, many CLL patients still need to continue treatment to maintain these responses, and recurrence sctuates often indicate a poor prognosisRecent studies on CLL have shown that combining BTK inhibitors with another Bcl-2 inhibitor can deepen the reaction and even shorten the cycle of treatment, resulting in complete remission in patientsTherefore, these findings provide a scientific basis for exploring the joint use of APG-2575 and acalabrutinib
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
